Special Issue

Inherited Metabolic Disorders: From Bench to Bedside

Message from the Guest Editors

Inherited metabolic disorders are a growing group of genetic disorders that affect cellular metabolism, resulting in a wide range of clinical signs and symptoms. The dynamics of scientific breakthroughs in this field is unprecedented, from newborn screening to new therapies, and is positively changing patients' lives. This Special Issue is devoted to publishing results on any features of inherited metabolic disorders, including newborn screening, diagnosis, basic research on molecular mechanisms, translational studies on novel therapies, and clinical investigations. Review articles on all these aspects are also welcome. The full spectrum of inherited metabolic disorders will be considered. including the lysosomal storage disorders. This Special Issue will provide a comprehensive view of the diagnostic, molecular and clinical aspects of various inborn errors of metabolism. It comprehensively covers many areas in the field of inherited metabolic disorders. and could be of interest to a broad range of readers including physicians and other health-related professionals, scientists, students, and inherited metabolic disorders communities.

Guest Editors

Dr. Fatima Macedo

- Cell Activation and Gene Expression Group, Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto. Portugal
- 2. Department of Medical Sciences, University of Aveiro (UA), 3810-193 Aveiro, Portugal

Dr. Hugo Rocha

- Newborn Screening, Metabolism and Genetics Unit, Human Genetics Department, National Institute of Health Doutor Ricardo Jorge, Porto, Portugal
- 2. Superior School of Health, Polytechnic Institute of Porto, Porto, Portugal

Deadline for manuscript submissions

closed (28 February 2023)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/123955

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).